New research shows how nerve cells can be protected against ALS

(Press-News.org) By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in collaboration with scientists at the Paris Brain Institute and Örebro University, have identified why certain nerve cells are resistant to the disease and what happens in the sensitive nerve cells when they are affected. The study, published in the scientific journal Genome Research, focuses on a hereditary form of ALS caused by mutations in the SOD1 gene. 

“We have gained a better understanding of how nerve cells can be protected against ALS. This opens up new targets for future therapies,” says Eva Hedlund, professor of neurochemistry at Stockholm University and head of the study.

The fatal disease amyotrophic lateral sclerosis (ALS) occurs when specific nerve cells, known as motor neurons, die and their connections – synapses – with skeletal muscles break down. However, a few groups of motor neurons are resistant to the disease, including those that control the muscles of the eye. The study shows that resistant motor neurons do not react significantly to the disease when it is caused by a hereditary SOD1 mutation, probably because they have very high basal levels of several nerve-protecting factors, such as Engrailed-1 (En1), Parvalbumin (Pvalb), Cd63, and Galanin (Gal). En1 is a transcription factor, a kind of “switch” for genes, which controls which proteins are produced in the cell.

“From previous research, we know that it can protect sensitive neurons from breaking down,” says one of the co-authors, Dr Melanie Leboeuf. “But the fact that the protective factor is produced at such high levels in the resistant motor neurons that control eye movements was a surprise.”

The research team was also able to show that sensitive motor neurons activate both harmful and protective responses to ALS.

“The nerve cells show clear signs of trying to protect themselves and activate genes that are normally high in the resistant nerve cells, such as En1, Pvalb, Cd63, and Gal. They also try to reestablish lost contact with the muscles by activating regeneration-promoting genes such as Atf3 and Sprr1a, even though these attempts ultimately fail,” says Eva Hedlund. 

The discovery of distinct basal and induced gene activity in different nerve cells opens up new possibilities for treatment.

“By trying to stimulate the cells to suppress the bad responses and instead further stimulate those that are important for survival, there is a chance that we may see positive results in the future,” says Eva Hedlund.

To understand which gene responses from the sensitive motor neurons that can best be used to predict the disease, the research team used machine learning, a branch of AI. This enabled the team to identify the genes VGF, INA, and PENK as strong indicators of disease across different mutations and that these genes could be used to identify ALS in human samples.

“We see a possibility that these genes could eventually be used as biomarkers for the disease and help with diagnosis and prognosis,” says Irene Mei, PhD student at the Department of Biomedical Sciences and Biophysics at Stockholm University and first author of the study. 

:

The article in Genome Research is available here: Transcriptional modulation unique to vulnerable motor neurons predicts ALS across species and SOD1 mutations
DOI: 10.1101/gr.279501.124


About ALS

The fatal disease ALS is characterized by the death of nerve cells in our brain and spinal cord, known as motor neurons, which control all the skeletal muscles in our body, leading to muscle breakdown and paralysis.  ALS is an incurable, progressive disease that is considered to be sporadic in 85–90% of cases, i.e., without clear family history. Regardless of the cause of ALS, the pathology where motor neurons are affected early and their connections to muscles are destroyed, is similar. 10–15% of cases are clearly hereditary and caused by mutations in various genes. One of the most common mutations is in the SOD1 gene (superoxide dismutase 1), which accounts for about 2% of all ALS cases and about 20% of genetic cases. Mutations in this gene cause the protein to fold incorrectly, which leads to problems in the cell when new toxic functions arise in the protein. Until now, it has been unknown whether different SOD1 mutations cause ALS in the same way. It has also been unknown why some motor neurons are sensitive while others are resistant to this mutation. Eva Hedlund's research group has previously shown that the cell's energy factories, mitochondria, are affected early in sensitive motor neurons when ALS is caused by mutations in the genes FUS, TARDBP, or C9ORF72:
http://www.nature.com/articles/s41467-025-59679-1
Su.se/English/news/new-research-on-als-opens-up-for-early-treatmenty-1.822423 There is currently no cure for ALS and no effective therapies for the sporadic disease. However, for familial ALS caused by certain known gene mutations, there is hope that specific treatments, which prevent the production of the mutated proteins, will soon be able to halt the progression of the disease. This will only work if removing the protein is less toxic to the cell than having the mutated form. For ALS linked to the SOD1 gene, such a treatment is recently available in the form of the drug Tofersen. The treatment is approved in the EU, but is not yet available to patients in Sweden. Contact

Eva Hedlund, Professor of Neurochemistry at the Department of Biochemistry and Biophysics, Stockholm University

E-mail: eva.hedlund@dbb.su.se, Phone: +46 (0) 76 113 09 11

about Eva Hedlund's research

about Eva Hedlund's research group

END